Table 1.
Association of anti-laminin 332 MMP with malignancies1 .
| Study | Year of publication | Origin of patients | No. of patients | No. of patients with malignancy |
|---|---|---|---|---|
| Leverkus et al. (72) | 1999 | Germany | 5 | 2 (40%) |
| Egan et al. (73) | 2001 | USA | 15 | 5 (29%) |
| Matsushima et al. (74)2 | 2004 | Japan | 16 | 5 (31%) |
| Terra et al. (47) | 2011 | Netherlands | 10 | 2 (20%) |
| Bernard et al. (56) Goletz et al., (60) |
2013 | France | [31] 4 |
[2 (6%)]3
2 (50%)3 |
| Hayakawa et al., (75) | 2014 | Japan | 4 | 2 (50%) |
| Goletz et al. (38) | 2019 | Germany, Japan, France, Italy, USA | 534 | 13 (25%) |
| Li et al., (76) | 2021 | Japan | [55]4,5 | [8 (14%)]5 |
| Qian et al. (40) | 2021 | Japan | 1334 | 22 (17%) |
| van Beek et al., (41) | 2021 | Germany | 134 | 4 (31%) |
| Total | 253 | 57 (23%) | ||
1only studies with more than 3 patients are indicated; 2review of Japanese cases; 3when 17 of the 31 reported sera were re-analyzed by the Biochip®-based indirect IF assay only 4 reacted with laminin 332. Of these 4 sera, 2 had a malignancy (60). As such, here, only latter data were included; 4 some patients may have also been included in other studies listed here; 5 data of this study were not included in the total numbers since all patients also appeared in the study of the same group by Qian et al. (40). Total numbers are shown in bold.